This is attributed to the haploinsufficiency of the CK1α gene (CSNK1A1) encoded at chromosome 5q32, which heightens MDS sensitivity to the effects of lenalidomide-induced CK1α degradation. The gene discussed is CSNK1A1; the disease is myelodysplastic syndrome.